This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Vaccinations in COPD

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Influenza vaccination

  • reduces serious illness and death in COPD patients
  • vaccines containing either killed live inactivated virus are recommended as they are more effective in elderly patients with COPD
  • population-based studies have reported a decreased risk of ischemic heart disease when they were vaccinated with influenza vaccine over many years

COVID-19 vaccination

  • SARS-CoV-2 (COVID-19) vaccination is recommended for people with COPD

Respiratory syncytial virus (RSV) vaccination

  • RSV vaccine is recommended for individuals over 60 years and/or with chronic heart or lung disease

Pneumococcal vaccination

  • the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been shown to reduce the incidence of community-acquired pneumonia in COPD patients <65 years with an FEV1 <40% predicted and in those with comorbidities (especially cardiac)
  • in adults >=65 years, the 13-valent conjugated pneumococcal vaccine (PCV13) has shown significant efficacy in reducing bacteremia and serious invasive pneumococcal disease (1)

Reference:

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.